Gastrointestinal Cancer | Specialty

Dr Klempner on Data for Givastomig Plus Nivolumab/mFOLFOX in Metastatic Gastric, Esophageal, and GEJ Adenocarcinoma

July 16th 2025

Samuel J. Klempner, MD, discusses the safety and efficacy of givastomig plus nivolumab and chemotherapy in metastatic gastric cancers.

Dr Weinberg on the Implications of Data With BXCL701 Plus Pembrolizumab in mPDAC

July 15th 2025

Benjamin A. Weinberg, MD, FACP, discusses the clinical implications of data with BXCL701 plus pembrolizumab in metastatic pancreatic ductal adenocarcinoma.

Supporting Community Practice Through Collaboration

July 15th 2025

Panelists discuss how communication between community oncologists and academic centers is essential for advancing gastrointestinal stromal tumor (GIST) treatment through clinical trial participation, molecular analysis, and the promising future of personalized therapy based on individual tumor mutation profiles.

Dr Bekaii-Saab on the Expanding Targeted Therapy Paradigm for Biliary Tract Cancers

July 14th 2025

Tanios S. Bekaii-Saab, MD, discusses current and emerging therapeutic targets for the treatment of patients with biliary tract cancers.

The OncFive: Top Oncology Articles for the Week of 7/6

July 12th 2025

The FDA approves Y-90 resin microspheres in HCC, the sNDA for decitabine/cedazuridine plus venetoclax in AML is under review, and more.

Oncologists Highlight Key Takeaways and Abstracts From the 2025 ESMO GI Cancers Congress

July 11th 2025

Oncology experts recap their key takeaways from the 2025 ESMO Gastrointestinal Cancers Congress.

FDA Grants Orphan Drug Designation to ADRX-0405 for Gastric Cancer

July 11th 2025

ADRX-0405 has received orphan drug designation from the FDA for the treatment of patients with gastric cancer.

The Prevalence of RAS Mutations in Metastatic PDAC

July 10th 2025

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the prevalence of RAS mutations in pancreatic ductal adenocarcinoma.

Studies Highlight Real-World Gaps in Third-Line mCRC and Evolving Role of Molecular Profiling in GI NETs

July 10th 2025

Rocío García-Carbonero, MD, discusses safety challenges in third-line mCRC and the role of molecular testing in aggressive GI neuroendocrine tumors.

Dr Vogel on the European Commission’s Marketing Authorization of Zanidatamab for HER2+ Biliary Tract Cancer

July 9th 2025

FDA Grants Orphan Drug Designation to FF-10832 for Biliary Tract Cancer

July 8th 2025

FF-10832—an investigational liposomal formulation of gemcitabine—has received orphan drug designation from the FDA for biliary tract cancer.

Evolving Gastrointestinal Stromal Tumor Treatment Landscape

July 8th 2025

Panelists discuss how newer clinical trials such as PEAK and INSIGHT are investigating combination therapies and mutation-specific treatment approaches to overcome secondary resistance mutations, while also exploring pan-KIT inhibitors and senescence-targeting strategies to improve outcomes.

Ripretinib Use in Advanced Gastrointestinal Stromal Tumors

July 8th 2025

Panelists discuss how most gastrointestinal stromal tumor (GIST) patients can tolerate approved agents with proper adverse effect management, the efficacy data from the INVICTUS and INTRIGUE trials that led to ripretinib's approval, and the unique adverse effects such as alopecia that distinguish ripretinib from other therapies.

ASCO 2025 Plenary — MATTERHORN

July 7th 2025

Drs Armstrong and Tawagi discussed key data from the phase 3 MATTERHORN trial, which were presented at the 2025 ASCO Annual Meeting.

Ivosidenib Has Preliminary Real-World Activity in IDH1-Mutated Cholangiocarcinoma

July 7th 2025

Ivosidenib was effective for the real-world treatment of patients with IDH1-mutated cholangiocarcinoma.

MAIC Analysis Suggests PFS, OS Advantage With Nivolumab/Ipilimumab Over Other First-Line IO Regimens in HCC

July 7th 2025

Efficacy results from a MAIC suggest potential benefit with nivolumab/ipilimumab over other first-line IO-based regimens in first-line unresectable HCC.

FDA Approves Y-90 Resin Microspheres for Unresectable HCC

July 7th 2025

The FDA has approved SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

mFOLFIRINOX Does Not Significantly Improve Survival Vs mFOLFOX6 in HER2– Metastatic Gastric/GEJ Adenocarcinoma

July 6th 2025

IRIGA trial comparing mFOLFIRINOX vs mFOLFOX6 shows mixed results in HER2-negative metastatic gastric and GEJ adenocarcinoma.

Five Under 5: Top Oncology Videos for the Week of 6/29

July 6th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.

RATIONALE-306 Subgroup Data Further Support First-line Tislelizumab/Chemo in Locally Advanced ESCC

July 5th 2025

Tislelizumab plus chemotherapy improves efficacy vs chemotherapy alone in locally advanced ESCC, including those with PD-L1 TAP of 5% or higher.